Dr. Vinay Prasad stepped down as FDA vaccines center director in March following controversies over vaccines, gene therapies and biotech drugs, his second departure from the role in less than a year.
Dr. Tracy Beth Hoeg departed the FDA's drug center leadership in May, saying she was fired from the job.
Dr. Marty Makary resigned from the FDA in May after months of complaints from health industry executives, anti-abortion activists and tobacco companies, particularly over lack of movement on flavored e-cigarettes.
Since Marty Makary's departure, the FDA cleared a series of new products, including new varieties of nicotine pouches and e-cigarettes.
The Trump administration, via the Department of Health and Human Services, filled four senior FDA positions on Tuesday, naming permanent directors for the drugs, vaccines and biologics, and tobacco centers plus a new AI and technology role.
Dr. Michael Davis was named permanent director of the FDA's Center for Drug Evaluation and Research, the agency's largest center, after serving in an acting role since Dr. Tracy Beth Hoeg's departure.
Karim Mikhail was named permanent director of the FDA's vaccines center, having joined the FDA last spring and stepped into the role after Dr. Vinay Prasad's resignation.
Bret Koplow, an attorney and career FDA official, was named director of the Center for Tobacco Products after serving in an acting role since the ouster of the previous director.
Jared Seehafer was appointed to a newly created FDA position overseeing artificial intelligence and technology.
Choose the stories that matter to you—and how you want to see them.
